Cargando…
Lack of ADAM2, CALR3 and SAGE1 Cancer/Testis Antigen Expression in Lung and Breast Cancer
Immunotherapy is emerging as a supplement to conventional cancer treatment, and identifying antigen targets for specific types of cancer is critical to optimizing therapeutic efficacy. Cancer/testis antigens are highly promising targets for immunotherapy due to their cancer-specific expression and a...
Autores principales: | Maheswaran, Emeaga, Pedersen, Christina B., Ditzel, Henrik J., Gjerstorff, Morten F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4529184/ https://www.ncbi.nlm.nih.gov/pubmed/26252478 http://dx.doi.org/10.1371/journal.pone.0134967 |
Ejemplares similares
-
Oncogenic cancer/testis antigens: prime candidates for immunotherapy
por: Gjerstorff, Morten F., et al.
Publicado: (2015) -
The role of GAGE cancer/testis antigen in metastasis: the jury is still out
por: Gjerstorff, Morten Frier, et al.
Publicado: (2016) -
Analysis of GAGE, NY-ESO-1 and SP17 cancer/testis antigen expression in early stage non-small cell lung carcinoma
por: Gjerstorff, Morten F, et al.
Publicado: (2013) -
CAR T-Cell Cancer Therapy Targeting Surface Cancer/Testis Antigens
por: Jakobsen, Mie K., et al.
Publicado: (2020) -
The Cancer/Testis Antigen Gene VCX2 Is Rarely Expressed in Malignancies but Can Be Epigenetically Activated Using DNA Methyltransferase and Histone Deacetylase Inhibitors
por: Jakobsen, Mie K., et al.
Publicado: (2021)